Read by QxMD icon Read

Clinical Lymphoma, Myeloma & Leukemia

Liat Shargian-Alon, Ronit Gurion, Pia Raanani, Dafna Yahav, Anat Gafter-Gvili
BACKGROUND: The reported data regarding the effects of hypomethylating agents (HMAs) on the risk of infections seem to be poorly documented and heterogeneous. We conducted a systematic review and meta-analysis of all randomized controlled trials comparing HMA-containing regimens with any other regimen administered to patients with myeloid neoplasms. MATERIALS AND METHODS: A comprehensive search was conducted until February 2018. Two reviewers appraised the quality of the trials and the extracted data...
May 28, 2018: Clinical Lymphoma, Myeloma & Leukemia
Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, Stefano Spada, Francesca Patriarca, Chiara Cerrato, Lorenzo De Paoli, Norbert Pescosta, Roberto Ria, Alessandra Malfitano, Pellegrino Musto, Luca Baldini, Tommasina Guglielmelli, Barbara Gamberi, Donato Mannina, Giulia Benevolo, Renato Zambello, Antonietta Pia Falcone, Antonio Palumbo, Arnon Nagler, Valeria Calafiore, Roman Hájek, Andrew Spencer, Mario Boccadoro, Sara Bringhen
BACKGROUND: High-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment with novel agents are the best options for patients with newly diagnosed multiple myeloma, increasing the rate of complete response (CR) and prolonging progression-free survival (PFS) and overall survival (OS). Indeed, the achievement of a CR is a predictor of long-term survival among transplant-eligible patients. However, it is unclear whether patients reaching a CR after induction treatment could receive less intense consolidation or avoid maintenance therapy...
May 28, 2018: Clinical Lymphoma, Myeloma & Leukemia
Kimaya Reddy, Myo Htut, Amrita Krishnan, Sanjeet S Dadwal
No abstract text is available yet for this article.
May 28, 2018: Clinical Lymphoma, Myeloma & Leukemia
Eman Z Kandeel, Ghada El Sayed, Nahla Elsharkawy, Dalia Negm Eldin, Hanan R Nassar, Dalia Ibrahiem, Randa Amin, Marwa Hanafi, Mohamed Khalil, Azza Kamel
BACKGROUND: The significance of FMS-like tyrosine kinase 3 (FLT3)-ITD mutation in acute myeloid leukemia (AML) prognosis has been well established. The aims of this study were to investigate the prognostic impact of the FLT3 protein (CD135) expression and its association with FLT3-ITD mutation, and to identify its role in minimal residual disease. PATIENTS AND METHODS: CD135 was measured by flow cytometry on leukemic blasts of 257 adults with de novo AML. High expression of CD135 ≥ 20% was correlated with clinical, laboratory, and other prognostic factors that influenced treatment outcome...
May 26, 2018: Clinical Lymphoma, Myeloma & Leukemia
Lauren Reed-Guy, Maarouf A Hoteit, Alfred L Garfall
No abstract text is available yet for this article.
May 26, 2018: Clinical Lymphoma, Myeloma & Leukemia
Jamie D Cavenagh, Rakesh Popat
Recent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges because of the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to optimally use new therapeutic agents. Panobinostat is the first histone deacetylase inhibitor approved for the treatment of multiple myeloma...
May 24, 2018: Clinical Lymphoma, Myeloma & Leukemia
Valeria Santini
In the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome (MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second, quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS. The research devoted to clarifying the mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced, mostly resulting from different approaches to the study of DNA methylation...
May 23, 2018: Clinical Lymphoma, Myeloma & Leukemia
Anita Geevarghese, John Mascarenhas
Chronic myelomonocytic leukemia (CMML) is a relatively uncommon hematologic malignancy that manifests as peripheral monocytosis, has varying degrees of bone marrow dysplasia, and is associated with poor outcomes. Despite a growing appreciation of the pathobiologic mechanisms driving CMML, current therapies have not clearly demonstrated any survival benefit. The complex pathobiology of CMML highlights the intricate aberrantly activated cellular pathways that influence disease phenotype and limit current treatment options...
May 23, 2018: Clinical Lymphoma, Myeloma & Leukemia
Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola, Ishmael Jaiyesimi
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous malignancy with diverse genetic abnormalities, clinical presentations, and outcomes. Known predictive and prognostic factors in AML include age, performance status, comorbidities, cytogenetics, and molecular mutations. Identifying prognostic and predictive factors can inform the choice of induction therapy and outcomes prediction. PATIENTS AND METHODS: A retrospective review was performed of 137 adult AML patients from 2010 to 2015...
May 23, 2018: Clinical Lymphoma, Myeloma & Leukemia
Nicholas J Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias Jabbour
The widespread adoption of Bcr-Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+ ) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of <25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (eg, ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual disease, the widespread use of allogeneic hematopoietic stem cell transplantation in first remission for patients with Ph+ ALL has been increasingly questioned...
May 22, 2018: Clinical Lymphoma, Myeloma & Leukemia
Coty H Y Cheung, Chi Keung Cheng, Kin-Mang Lau, Rosalina K L Ip, Nelson C N Chan, Tommy H C Tam, Raymond S M Wong, Radha Raghupathy, Natalie P H Chan, Margaret H L Ng
BACKGROUND: Previous studies in Western countries demonstrated BRAF V600E mutation only in a small subset of multiple myeloma (MM) patients. However, the prevalence and clinicopathologic significances of this mutation remain unclear in Chinese MM patients. PATIENTS AND METHODS: We studied diagnostic bone marrow samples from 205 Chinese MM patients by allele-specific PCR to detect BRAF V600E mutation and by high-resolution melting assay to detect KRAS and NRAS mutations...
May 15, 2018: Clinical Lymphoma, Myeloma & Leukemia
Jose F Falantes, Francisco J Márquez-Malaver, Cristina Calderón-Cabrera, Begoña Pedrote, María L Martino, Jose González, Ildefonso Espigado, Jose A Pérez-Simón
BACKGROUND: The prognosis of patients with lower-risk myelodysplastic syndrome (LR-MDS) is very heterogeneous. In addition to survival estimates, identification of factors related to the probability of leukemic progression might help prognosis assessment. PATIENTS AND METHODS: The present study is a retrospective analysis of 409 patients with primary LR-MDS. The probability of leukemic progression was estimated in the competing risk framework by the cumulative incidence method considering death without acute myeloid leukemia (AML) as a competing event...
May 10, 2018: Clinical Lymphoma, Myeloma & Leukemia
Alex F Herrera, Arturo Molina
Antibody-drug conjugates (ADCs) are tripartite molecules consisting of a monoclonal antibody, a covalent linker, and a cytotoxic payload. ADC development has aimed to target the specificity inherent in antigen-antibody interactions to deliver potent cytotoxins preferentially to tumor cells and maximize antitumor activity and simultaneously minimize off-target toxicity. The earliest ADCs provided disappointing results in the clinic; however, the lessons learned regarding the need for human or humanized antibodies, more stable linkers, and greater potency payloads led to improved ADCs...
May 10, 2018: Clinical Lymphoma, Myeloma & Leukemia
Jill A Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J Fram, Douglas V Faller
Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly (≥60 years old) patients with AML. Published literature on the topic was scant, and the review included only 22 articles examining outcomes...
May 10, 2018: Clinical Lymphoma, Myeloma & Leukemia
Joanna Gora-Tybor, Tomasz Sacha, Joanna Wącław, Joanna Niesiobędzka-Krężel, Olga Grzybowska-Izydorczyk, Ewa Mędraś, Izabela Dereń-Wagemann, Elżbieta Patkowska, Ilona Seferyńska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Wątek, Katarzyna Kotwica-Mojzych, Ewa Wasilewska, Krzysztof Warzocha, Krzysztof Jamroziak
No abstract text is available yet for this article.
May 9, 2018: Clinical Lymphoma, Myeloma & Leukemia
Adi Shacham-Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Helman, Liat Shargian, Anna Gourevitch, Evgeni Chubar, Roy Ratzon, Uri Rozovski
BACKGROUND: The strict recruitment criteria of patients for clinical trials often lead to reduced generalizability of the findings. We studied how ponatinib is used outside clinical trials in patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: The present retrospective study included all patients with a diagnosis of CML who had received ponatinib in 7 medical centers in Israel. RESULTS: From 2011 to 2016, we identified 37 patients with CML who had received ponatinib, 21 in the chronic phase and 16 in the advanced phase...
May 7, 2018: Clinical Lymphoma, Myeloma & Leukemia
Mayur S Narkhede, Bruce D Cheson
Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in the front-line setting. The long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus, clinical trials require approximately 5 to 8 years from activation to completion and analysis of outcomes...
May 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Sundar Jagannath, Rafat Abonour, Brian G M Durie, Cristina Gasparetto, James W Hardin, Mohit Narang, Howard R Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E Dawn Flick, Amit Agarwal, Robert M Rifkin
BACKGROUND: The treatment landscape for multiple myeloma (MM) has undergone recent changes with the regulatory approval of several new therapies indicated for second- and later-line disease. Using data from Connect MM, the largest multisite, primarily community-based, prospective, observational registry of MM patients in the United States, selection of second-line treatments was evaluated during a 5-year period from 2010 to 2016. PATIENTS AND METHODS: Eligible patients were aged ≥ 18 years, had newly diagnosed MM ≤ 2 months before study entry, and were followed for up to 8 years...
May 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
Tania Jain, Heidi E Kosiorek, Shu T Kung, Vishal S Shah, Amylou C Dueck, Veronica Gonzalez-Calle, Susan Luft, Craig B Reeder, Roberta Adams, Pierre Noel, Jeremy T Larsen, Joseph Mikhael, Leif Bergsagel, A Keith Stewart, Rafael Fonseca
BACKGROUND: The hematologic response is critical in patients with light chain amyloidosis because a good response is known to improve organ response and overall survival. We present a retrospective analysis to compare the hematologic and organ response in patients who received bortezomib-based therapy before autologous stem cell transplantation (ASCT) versus those who received non-bortezomib-based therapy before ASCT and those who underwent ASCT at diagnosis. PATIENTS AND METHODS: Of a total of 63 patients who underwent ASCT for light chain amyloidosis, 34 received bortezomib-based therapy before ASCT (Bor-ASCT) and 29 did not receive bortezomib therapy (non-Bor-ASCT)...
May 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
William D Marrero, Alexis Cruz-Chacón, Christian Castillo, Fernando Cabanillas
No abstract text is available yet for this article.
May 4, 2018: Clinical Lymphoma, Myeloma & Leukemia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"